Innovation Competition Concerns

1. Introduction

Innovation competition refers to competition based not merely on the price or quality of existing products, but on firms' efforts to develop new products, technologies, processes, services, or substantially improved products.

Competition law is increasingly concerned that conduct may reduce innovation even where the immediate effect on prices is difficult to demonstrate. This is particularly important in pharmaceuticals, biotechnology, digital markets, chemicals, semiconductors, telecommunications, artificial intelligence, and other R&D-intensive industries.

Innovation concerns commonly arise through:

• mergers eliminating an important R&D competitor;
• acquisition of a nascent or potential competitor;
• exclusion of competing technologies;
• denial of access to essential technological inputs;
• acquisition of competing research pipelines;
• suppression of interoperability;
• exclusive licensing or technology agreements;
• patent-related exclusionary conduct;
• information exchange affecting R&D;
• strategic conduct that raises rivals' innovation costs.

The European Commission has expressly recognized that innovation may constitute an important parameter of competition, including where the precise future products resulting from R&D are uncertain.

2. Legal Basis

A. Abuse of Dominance

A dominant undertaking may infringe competition law where it uses its market power to prevent or discourage competing innovation.

Potential forms include:

1. refusal to supply technological inputs;
2. discriminatory access to infrastructure;
3. exclusionary licensing;
4. tying or bundling;
5. predatory or exclusionary pricing;
6. interoperability restrictions;
7. strategic acquisition of innovative rivals.

The essential issue is whether the conduct protects or extends existing market power by weakening competitive innovation.

B. Anticompetitive Agreements

Innovation can also be harmed by agreements between competitors concerning:

• R&D allocation;
• technology licensing;
• market allocation;
• restrictions on developing competing technologies;
• exchange of sensitive R&D information;
• joint ventures that eliminate independent innovation;
• agreements restricting the use of alternative technologies.

However, legitimate R&D cooperation can also generate efficiencies. Competition analysis therefore needs to distinguish between innovation-enhancing cooperation and agreements that suppress independent innovation.

3. Innovation as a Parameter of Competition

Traditional competition analysis frequently examines:

Price → Output → Quality → Consumer choice

Innovation analysis adds another dimension:

R&D → technological development → future products → future competition

Consequently, a transaction may be problematic even where:

• the parties are not significant competitors in today's product market;
• their existing products overlap only modestly;
• one party is still developing its product;
• the relevant future market does not yet exist;
• competition would occur through competing R&D pipelines.

This is particularly important for nascent competition.

4. Main Innovation Competition Concerns

A. Elimination of an Innovation Rival

A large incumbent may acquire a smaller firm principally because the smaller firm is developing a technology capable of challenging the incumbent.

The competitive harm may occur even before the smaller firm's technology reaches commercial maturity.

The authority may therefore examine:

• R&D expenditure;
• patent portfolios;
• research pipelines;
• technical capabilities;
• probability of successful development;
• access to capital;
• relationships with customers;
• scientific personnel;
• internal documents concerning competitive threats.

B. Nascent Competitor Acquisitions

A particularly important category is the acquisition of a nascent competitor.

The acquired company may have:

• few current sales;
• no established market share;
• an uncommercialized product;
• an early-stage technology.

Nevertheless, it may possess substantial competitive significance because it represents an alternative technological trajectory.

This theory was central to several modern technology and life-sciences merger investigations.

5. Innovation Markets and R&D Competition

Competition authorities may examine competition at different levels.

Product-market competition

Competition between existing products.

Technology-market competition

Competition between technologies capable of performing similar functions.

R&D competition

Competition between firms attempting to develop future products.

Innovation-space competition

A broader inquiry into firms possessing capabilities and assets capable of producing future innovations.

The European Commission's experience with Dow/DuPont is particularly important because it examined innovation through R&D pipelines, innovation capabilities and future products rather than relying exclusively upon existing product-market shares.

6. Important Case Laws

1. Illumina, Inc. v. GRAIL, Inc. / FTC

Authority: U.S. FTC and Fifth Circuit proceedings
Industry: DNA sequencing and cancer detection

Illumina, the leading provider of next-generation sequencing technology, sought to acquire GRAIL, which was developing multi-cancer early-detection tests.

The FTC alleged that the transaction could reduce innovation because GRAIL was participating in an innovation race with other developers while relying upon sequencing technology supplied by Illumina.

The FTC ultimately ordered divestiture after reversing an Administrative Law Judge's dismissal. The Fifth Circuit subsequently found substantial evidence supporting the FTC's determination concerning competitive harm, and Illumina announced that it would divest GRAIL.

Principle

A vertical acquisition can raise innovation concerns where:

• the acquiring company controls an important technological input;
• the target is an innovative downstream competitor;
• rivals depend upon the acquirer's technology;
• the acquisition creates incentives to disadvantage competing innovators.

The case is especially important for the concept of an innovation race.

2. FTC v. Illumina / Pacific Biosciences

Industry: DNA sequencing

Illumina proposed acquiring Pacific Biosciences, another sequencing technology company.

The FTC alleged that the transaction would eliminate PacBio as a nascent competitive threat and enable Illumina to maintain its position in next-generation DNA sequencing.

The parties ultimately abandoned the transaction in January 2020.

Principle

A firm does not necessarily need a substantial existing market share to constitute an important competitive constraint.

A developing technology may itself represent an important source of future competition.

3. Dow Chemical / DuPont

European Commission merger decision

Industry: Agricultural chemicals and crop protection

The Commission examined whether the merger would reduce innovation competition in agricultural chemicals.

The parties were significant participants in R&D for new crop-protection products. The Commission examined:

• R&D pipelines;
• innovation capabilities;
• researchers;
• product-development projects;
• future products;
• technological capabilities.

The Commission ultimately required substantial remedies, including divestiture of overlapping R&D capabilities.

The case became a major reference point for the European Commission's innovation theory of harm. The Commission's later policy analysis identifies Dow/DuPont as an example where innovation was important because agricultural products need to adapt to resistant weeds and insects and changing regulatory requirements.

Principle

Merger control can protect future innovation competition, not merely existing product competition.

4. Bayer / Monsanto

European Commission

Industry: Seeds and agricultural chemicals

The Bayer/Monsanto transaction raised concerns concerning competition in agricultural innovation.

The Commission examined innovation relating to:

• crop-protection products;
• seeds;
• traits;
• digital agriculture;
• R&D pipelines;
• future agricultural technologies.

The importance of innovation was particularly significant because biological resistance and regulatory developments can make continued innovation necessary.

The Commission has specifically identified Bayer/Monsanto alongside Dow/DuPont as a case in which innovation was an important competitive parameter.

Principle

Where technological change and biological resistance require continuous development of new products, elimination of an important R&D competitor can constitute a significant competitive concern.

5. Illumina / GRAIL — European Commission

The transaction was also investigated by the European Commission.

The Commission found that innovation was a key competitive parameter in the development of multi-cancer early-detection tests.

GRAIL and other developers were engaged in an innovation race to develop early cancer-detection technologies, while Illumina supplied the sequencing technology necessary for that development.

Principle

Competition authorities may protect innovation even where:

• the ultimate product is not yet fully developed;
• the precise future market is uncertain;
• the innovation race has not yet produced a mature commercial product.

6. Meta Platforms / Within Unlimited

Authority: U.S. federal courts / FTC
Industry: Virtual reality fitness

The FTC challenged Meta's acquisition of Within, arguing that the acquisition could eliminate competition between Meta and Within in virtual-reality fitness.

The FTC's theory included the possibility that Meta could otherwise enter the market independently and compete through its own innovation and product development.

The court ultimately denied the FTC's request for a preliminary injunction, illustrating that innovation theories must still satisfy the applicable evidentiary and legal requirements. The FTC's subsequent materials describe the case as involving potential-competition and innovation concerns.

Principle

Potential competition can include the competitive pressure generated by the possibility that a powerful company may independently enter and innovate.

7. Hyundai Heavy Industries Holdings / Daewoo Shipbuilding & Marine Engineering

European Commission

Industry: Shipbuilding / LNG carriers

The Commission considered innovation in relation to large LNG carriers.

Innovation involved:

• reducing LNG boil-off;
• improving cost-effectiveness;
• reducing fuel consumption;
• reducing CO₂ emissions.

The case demonstrates that innovation concerns are not limited to digital or pharmaceutical industries. They can arise in traditional industrial sectors where technological development is an important competitive parameter.

Principle

Innovation competition can exist in capital-intensive industrial markets, even where innovation occurs through engineering and manufacturing improvements rather than software.

7. Comparison of Major Cases

8. How Authorities Assess Innovation Competition

Authorities may examine several factors.

1. R&D capabilities

Who possesses the personnel, laboratories, patents and technology necessary to innovate?

2. Innovation pipelines

What products or technologies are currently being developed?

3. Competitive closeness

Are the parties pursuing similar technological solutions?

4. Probability of successful development

Is the innovation commercially or technically plausible?

5. Incentive to innovate

Would the transaction or conduct reduce the firm's incentive to continue developing the technology?

6. Ability to foreclose

Does the dominant firm control an important:

• platform;
• dataset;
• laboratory;
• semiconductor;
• API;
• operating system;
• sequencing technology;
• distribution channel;
• infrastructure?

7. Effect on rivals' R&D

Could rivals face:

• higher costs;
• delayed access;
• reduced interoperability;
• discriminatory licensing;
• reduced technical support;
• reduced access to data?

8. Consumer effects

The authority may ultimately ask whether innovation harm could result in:

• fewer products;
• slower technological progress;
• reduced quality;
• higher prices;
• fewer choices;
• delayed technological development.

9. Innovation Competition and Digital Markets

Digital markets create particularly strong innovation concerns because firms often compete through:

• algorithms;
• AI models;
• data;
• APIs;
• interoperability;
• cloud infrastructure;
• operating systems;
• app ecosystems;
• digital platforms.

A dominant platform may theoretically reduce innovation by preventing rival developers from obtaining access to the infrastructure necessary to compete.

For example:

Dominant platform → controls API/data/access → innovative rival depends upon platform → access restricted → rival's development weakened → future competition reduced

This can produce competitive harm even where the rival has insignificant current revenues.

10. Innovation Competition and Intellectual Property

Intellectual-property rights generally encourage innovation by permitting innovators to obtain returns on R&D.

However, competition concerns can arise where IP rights are used strategically to exclude competing innovation.

Potential concerns include:

• refusal to license;
• discriminatory licensing;
• patent portfolio accumulation;
• patent settlements;
• exclusionary patent strategies;
• standard-essential patent conduct;
• licensing restrictions;
• acquisition of competing technologies.

Competition law therefore seeks to balance:

Incentive to innovate
against
Preservation of competition needed to generate future innovation.

11. Innovation Competition in Mergers

A simplified analytical framework is:

Step 1: Identify existing competition.

↓

Step 2: Identify R&D and innovation pipelines.

↓

Step 3: Determine whether the parties are innovation competitors.

↓

Step 4: Examine whether the target is a nascent or potential competitor.

↓

Step 5: Determine whether the acquisition removes an independent innovation pathway.

↓

Step 6: Examine foreclosure possibilities.

↓

Step 7: Evaluate efficiencies and innovation benefits.

↓

Step 8: Consider structural or behavioural remedies.

12. Efficiencies and Innovation Benefits

An innovation-related merger is not automatically unlawful.

Parties may argue that the transaction will:

• combine complementary technologies;
• reduce duplication;
• increase R&D funding;
• accelerate product development;
• combine patents;
• improve manufacturing;
• facilitate commercialization;
• reduce development costs.

Authorities must therefore distinguish between:

genuine innovation efficiencies

and

elimination of independent innovation competition.

The Illumina/GRAIL proceedings demonstrate the importance of substantiating claimed efficiencies rather than relying upon general assertions that integration will produce beneficial innovation.

13. Remedies

Where innovation competition is threatened, possible remedies include:

Structural remedies

• divestiture of a business;
• divestiture of R&D assets;
• transfer of intellectual property;
• separation of laboratories;
• divestiture of a competing technology.

Behavioural remedies

• non-discriminatory access;
• licensing commitments;
• interoperability;
• firewall arrangements;
• restrictions on use of competitively sensitive information;
• continued supply obligations.

Structural remedies are particularly significant where the underlying problem is the elimination of an independent innovation competitor.

The Illumina/GRAIL matter illustrates this approach: the FTC ultimately required divestiture, and Illumina subsequently announced that it would unwind the acquisition.

14. Challenges in Proving Innovation Harm

Innovation cases are often difficult because innovation is inherently uncertain.

Authorities may need to determine:

• whether a technology will actually succeed;
• when it will reach the market;
• whether consumers will adopt it;
• whether another technology will replace it;
• whether the target would have remained independent;
• whether the acquiring company would independently develop competing technology.

Therefore, evidence can include internal business documents, R&D plans, patent filings, scientific publications, investment records, technical personnel evidence and communications concerning competitive threats.

The Illumina/GRAIL proceedings demonstrate that innovation theories can involve substantial disputes over the evidence and the appropriate standard for establishing future competitive harm.

15. Key Distinction: Product Competition vs Innovation Competition

16. Conclusion

Innovation competition concerns arise when conduct or transactions threaten the competitive process through which new technologies, products or services are developed.

The principal competition-law concerns include:

1. elimination of an R&D competitor;
2. acquisition of nascent competitors;
3. suppression of potential entry;
4. foreclosure of innovative rivals;
5. restriction of technological access;
6. elimination of competing R&D pipelines;
7. misuse of intellectual property;
8. restrictions on interoperability;
9. acquisition of critical technological inputs;
10. reduction in incentives to innovate.

The modern approach therefore recognizes that competition is not limited to what firms sell today; it may also concern what competing firms are capable of developing tomorrow. The Dow/DuPont, Bayer/Monsanto, Illumina/PacBio and Illumina/GRAIL matters are particularly important for understanding this shift toward protection of R&D, nascent competition and innovation races.